TNPO2

Across TCGA pan-cancer cohorts, TNPO2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TNPO2 data layer compared with 28 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TNPO2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TNPO2 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

HNSC, CCRCC, and UCEC are the cancer types where TNPO2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	IV	0.512	0.835	<.001	48	view →
CCRCC	DFS	Tertile	All	0.568	0.849	.004	41	view →
UCEC	OS	Median	All	0.899	1.000	.004	32	view →
GBM	OS	Tertile	All	0.681	0.360	<.001	15	view →
LSCC	DFS	Median	II,III,IV	0.973	0.877	.023	10	view →
PDAC	OS	Tertile	All	0.286	0.511	.017	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TNPO2–HNSC (DFS)

Open the HNSC breakdown →